

## AMENDMENT TO THE CLAIMS

Please amend the claims as follows.

1. (Currently Amended)      An isolated and purified antiviral polypeptide comprising between 14 and 18 amino acids or derivative thereof comprising a tandem repeat of the apoE<sub>141-149</sub> tandem repeat set forth in of SEQ ID No 2, wherein said polypeptide comprises one or more amino acid substitutions of tryptophan (W) for leucine (L) or a truncation thereof, characterised in that at least one Leucine (L) residue of SEQ ID No. 2 is replaced by a Tryptophan (W) or derivatives thereof.
2. (Cancelled)
3. (Cancelled)
4. (Currently Amended)      The polypeptide or derivative thereof according to of claim 1 wherein at least two W substitutions are made.
5. (Currently Amended)      The polypeptide or derivative thereof according to of claim 1 wherein at least one further leucine amino acid is replaced with Phenylalanine (F) or is deleted.
6. (Currently Amended)      The polypeptide or derivative thereof according to of claim 1 with the amino acid sequence: WRKWRKRWWWRKWRKRWW (SEQ ID No. 3); WRKWRKRWRKWRKR (SEQ ID No. 4); WRKWRKRWWLRKLRKLL (SEQ ID No. 5); or WRKWRKRWFFRKWRKRFF (SEQ ID No. 55).
7. (Cancelled)

8. (Currently Amended)      ~~The polypeptide or derivative thereof according to~~ of  
claim ~~7~~ 1 wherein the ~~an~~ amino acid is added to the N terminal, C terminal and/or  
between the ninth and tenth amino acids of SEQ ID No.2.
9. (Currently Amended)      ~~The polypeptide or derivative thereof according to~~ of  
claim 8 comprising WRKWRKRWWWRKWRKRWWWR (SEQ ID No. 66).
10. (Cancelled)
11. (Cancelled)
12. (Currently Amended)      An isolated and purified antiviral polypeptide or  
~~derivative thereof~~ comprising YRKYRKRYYYRKYRKRY (SEQ ID No. 6).
13. (Currently Amended)      An isolated and purified antiviral polypeptide or  
~~derivative thereof~~ comprising LRKLRKRLLLRKLRK (SEQ ID No. 7).
14. (Currently Amended)      An isolated and purified antiviral polypeptide or  
~~derivative thereof~~ comprising LRKLRKRLRKLRKR (SEQ ID No. 8).
15. (Currently Amended)      An isolated and purified antiviral polypeptide or  
~~derivative thereof~~ comprising LRKLRKLRKLRKLRKLRK (SEQ ID No. 9).
16. (Currently Amended)      A composition, comprising the polypeptide or  
~~derivative thereof according to~~ of claim 1.
17. (Cancelled)
18. (Cancelled)

19. (Currently Amended) A method of ~~preventing and/or treating a viral infection~~ inhibiting viral replication, comprising administering to a subject in need of such treatment a therapeutically effective amount of the polypeptide or ~~derivative thereof according to~~ of claim 1.
20. (Cancelled)
21. (Cancelled)
22. (Cancelled)
23. (New) The method of claim 19, wherein the polypeptide is the polypeptide of claim 4.
24. (New) The method of claim 19, wherein the polypeptide is the polypeptide of claim 5.
25. (New) The method of claim 19, wherein the polypeptide is the polypeptide of claim 6.
26. (New) The method of claim 19, wherein the polypeptide is the polypeptide of claim 8.
27. (New) The method of claim 19, wherein the polypeptide is the polypeptide of claim 9.
28. (New) The method of claim 19, wherein the polypeptide is an isolated and purified antiviral polypeptide comprising YRKYRKRYYYRKYRKRY (SEQ ID No. 6).

29. (New) The method of claim 19, wherein the polypeptide is an isolated and purified antiviral polypeptide comprising LRKLRKRLLLRKLRK (SEQ ID No. 7).
30. (New) The method of claim 19, wherein the polypeptide is an isolated and purified antiviral polypeptide comprising LRKLRKRLRKLRKR (SEQ ID No. 8).
31. (New) The method of claim 19, wherein the polypeptide is an isolated and purified antiviral polypeptide comprising LRKLRKLRKLRKLRKLRK (SEQ ID No. 9).
32. (New) An isolated and purified antiviral polypeptide derived from the apoE141-149 tandem repeat set forth in SEQ ID No. 2 selected from the group consisting of:
- WRKWRKRWWRKWRKRWW (SEQ ID No. 52),  
WRKWRKRWRKWRKRW (SEQ ID No. 53),  
WRKWRKRWWFRKWRKRWW (SEQ ID No. 54),  
WRKCRKRCWWRKCRKRCW (SEQ ID No. 56),  
LRKLRKRLWWRKWRKRWW (SEQ ID No. 57),  
LRKLRKRLLLRKLRKRWW (SEQ ID No. 58),  
LRKLRKRLWWRKWRKRLL (SEQ ID No. 59),  
WRKWRKRLLLRKLRKRLL (SEQ ID No. 60),  
WRKLRKRLLLRKLRKRLL (SEQ ID No. 61),  
WRKWRKFFFRKWRKRWW (SEQ ID No. 62),  
WRKWRKRWWFRKFRKRFF (SEQ ID No. 63),  
RRKRRKRRRRRKRRKRRR (SEQ ID No. 64), and  
KRKKRKRRKKRKKRKRKK (SEQ ID No. 65).
33. (New) A method of inhibiting viral replication, comprising administering to a subject in need of such treatment a therapeutically effective amount of the polypeptide of claim 32.